AcuBiz Consulting

#consulting company focusing on #pharma, #biotech, #training, molecular diagnostics, and #marketresearch reports based in #Malaysia,

[Sadhguru @SadhguruJV]

Thank you for your support, Little One. With that sweet voice, all you have to do is say La la le le le le…everyone will come. And for you, we will make it happen. Love & Blessings. -Sg. #SaveSoil @cpsavesoil

[AcuBiz Consulting @acubiz]

#MedicalDevice demand is growing in #ASEAN with a population of >650 million.
Our Malaysia & Indonesia #Medicaldevice #distributor #database assists foreign companies to fast screen potential distribution partners and connect with them. https://t.co/8fp3DK92Rh

[AcuBiz Consulting @acubiz]

India has the potential to become a major player in the world of Precision Medicine. Who would drive this? What is needed to grow more? https://t.co/xMzhbGDVAQ via @acubiz

[AcuBiz Consulting @acubiz]

The diverse Indian population, representing 17.7% of the global population, needs a bigger, better database for Precision Medicine https://t.co/xMzhbGDVAQ via @acubiz

[AcuBiz Consulting @acubiz]

India is quickly picking up speed in the Precision Medicine race- how far has it come? https://t.co/xMzhbGDVAQ via @acubiz

[AcuBiz Consulting @acubiz]

#Genome #CRISPR

[CRISPR News 🧬 @CRISPR_News]

Revolutionary CRISPR-based Genome Editing System Destroys Cancer Cells ‘Permanently’ in Lab. "There are no side effects" Prof. Dan Peer https://t.co/GY3Fsv7J5g

[Nicole Lim @nicolelim_127]

The choice of test type depends on wanting accuracy or speed, choosing the most suitable test at the right time. #SARSCoV2 #qPCR #antigen #antibody ⁦@acubiz⁩ https://t.co/ewxHEe9LgX

[AcuBiz Consulting @acubiz]

#malaria

[Nicole Lim @nicolelim_127]

#malaria parasites keep a low profile in the body when resources are scarce, making people less sick and allowing it to remain undetected. #parasite #immunology
https://t.co/IxO4yQUmdh @acubiz

[AcuBiz Consulting @acubiz]

Another highly motivated student just completed her internship with us. We take pride in offering valuable experience to such talented students with the required tenacity and commitment.
Wishing @JiaJhing a bright future.
https://t.co/ybmvtEDf1Y #Biotech #internship

[nature @Nature]

Months after infection with SARS-CoV-2, some people are still battling crushing fatigue, lung damage and other symptoms of ‘long COVID’. https://t.co/axSpGtJt2N

[Business Insider @BusinessInsider]

Why is insulin so expensive?

[nature @Nature]

Different SARS-CoV-2 strains haven’t yet had a major impact on the course of the pandemic, but they might in future. https://t.co/Ld5RIacj5A

[Gautami Kundan @GautamiKundan]

Higher Viral Load In COVID-19 Asymptomatic Patients https://t.co/cBTrA4OGPW

#COVID19

@acubiz

[Jia Jhing Sia @JiaJhing]

Antiviral used to treat cat coronavirus also works against SARS-CoV-2 https://t.co/XjURvaQL0s via @medical_xpress

@acubiz

[Jia Jhing Sia @JiaJhing]

Cool technology!! If they can improve the power conversion efficiency, this could be the next big thing!

Windows become transparent solar panels with added nanoparticles https://t.co/RHI47RIP0W

@acubiz

[AcuBiz Consulting @acubiz]

"GenePath opened Pune’s first COVID-19 drive up collection centre" - Dr Nikhl Phadke, Founder of Genepath Dx, Pune, India
The link for the full interview of Dr Phadke by our research analyst, @GautamiKundan about COVID-19 testing trends in India as below.
https://t.co/Ih9wLLUkEw

[AcuBiz Consulting @acubiz]

"We were the first Indian organization to receive regulatory approval in India for clinical testing of COVID-19 as well as for our COVID-19 qRT-PCR test kits" - Dr Phadke, Founder, GenePath Dx, India
https://t.co/Ih9wLLUkEw via @acubiz @GenepathDx @GautamiKundan

[Gautami Kundan @GautamiKundan]

I recently interviewed @nikhilphadke, Founder and CSO of Pune, India-based GenePath Dx. We discussed about the COVID-19 situation in India and how his company has responded to the pandemic.

Thank you @acubiz

#COVID19 #Covid19india #IVD
#GenePathDx
https://t.co/5nplTijWQ5

[Gautami Kundan @GautamiKundan]

AstraZeneca Launches 30,000-Patient Phase III U.S. Trial of COVID-19 Vaccine https://t.co/zvdEtzwTUb via @GENbio

#Covid19 #COVID19vaccine

@acubiz

[Craig Spencer MD MPH @Craig_A_Spencer]

This post from @DrTomFrieden asks the questions we need to know before we label convalescent plasma a “major therapeutic breakthrough” for #COVID19.